ANIK Overview

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Wall Street analysts forecast ANIK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIK is16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anika Therapeutics Inc revenue for the last quarter amounts to 29.61M USD, increased 13.16

Anika Therapeutics Inc. EPS for the last quarter amounts to -0.37 USD, increased 8.82

Anika Therapeutics Inc (ANIK) has 235 emplpoyees as of May 11 2026.

Today ANIK has the market capitalization of 196.52M USD.